Akanksha Mittal
Global & US Medical Affairs Leader Galderma
Seminars
Despite rapid expansion across mainstream inflammatory indications, many rare and under-researched cutaneous disorders continue to face limited therapeutic innovation, poor translational models, delayed diagnosis and minimal investment attention. This workshop will explore development opportunities across indications including alopecia areata, androgenetic alopecia, severe acne subtypes, pigmentary disorders such as melasma and vitiligo, dermal drug reactions and other niche inflammatory and fibrotic conditions where unmet need remains high despite significant patient burden.
Attendees will discuss how developers can prioritise underserved indications, generate meaningful translational evidence in small patient populations, and build scalable strategies that translate rare disease insights into broader platform and pipeline opportunities.
Key Objectives:
- Why are rare and under-researched cutaneous indications becoming increasingly attractive for developers and investors?
- How can companies overcome challenges in diagnosis, patient stratification and patient identification across heterogeneous and underserved populations?
- What translational, biomarker and clinical evidence is required to demonstrate value in smaller populations with limited historical research?
- How can success in niche indications such as Lichen Sclerosus, Vitiligo, Pemphigoid Nodularis, Prurigo Nodularis, Pyoderma gangrenosum or Generalized Pustular Psoriasis inform broader therapeutic development across chronic inflammatory and regenerative disease?
- What are the key scientific, operational and commercial risks when developing therapies in smaller and historically overlooked patient populations?
- Positioning new mechanisms of action such as IL-31 inhibition and long-acting drugs as a potentially best-in-class alternative in moderate-to-severe atopic dermatitis
- Assessing how infrequent maintenance dosing compares with Dupixent, Ebglyss and oral JAK inhibitors, improving convenience and long-term adherence potential, to strengthen differentiation in an increasingly crowded AD market
- Understanding whether deeper and sustained responses with highly selective IL-13 blockade can redefine competitive benchmarks for efficacy, safety and patient preference, aligning clinical outcomes with payer and physician expectations, to maximise uptake and commercial value ahead of planned Phase 3 initiation in 2H 2026
